Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Discover effective ways to generate quick cash flow that can help you manage your finances and meet immediate needs.
22,355 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
When AI dominates headlines, investors often fear every software stock will crumble. This piece digs into whether fig...
Markets grapple with a hypothetical energy shock after a White House remark suggesting oil could surge to $200 per ba...
Institutional investors are eyeing Millrose Properties’ land-banking model as the housing market shifts. This look at...
The CSWC 2026 earnings transcript offers a clear read on the company’s income engine, credit quality, and capital str...
Two leaders, two paths: Nuscale Power’s SMRs and Nano Nuclear Energy’s microreactors. This guide breaks down commerci...
A Broadway revival signals more than a marquee moment. It’s a chance to see how top-tier talent negotiates money, man...
MicroStrategy offloads 32 BTC to cover dividend payouts on its perpetual preferred shares, signaling a shift from a p...
Three U.S. utility stocks are delivering reliable dividend income as rate-base growth supports earnings, offering a d...
A $650,000 portfolio could potentially cover a yearly luxury trip if the income approach is right, balancing high-yie...
Strategy’s perpetual preferred stock has fallen from the $100 issuance price to the mid-$70s, prompting widespread in...
Investors eye dividend income to replace a $70,000 salary. This piece breaks down three yield-based paths and the cap...